Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins.

Poruchynsky MS, Komlodi-Pasztor E, Trostel S, Wilkerson J, Regairaz M, Pommier Y, Zhang X, Kumar Maity T, Robey R, Burotto M, Sackett D, Guha U, Fojo AT.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1571-6. doi: 10.1073/pnas.1416418112. Epub 2015 Jan 20.

2.

Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.

Basseville A, Tamaki A, Ierano C, Trostel S, Ward Y, Robey RW, Hegde RS, Bates SE.

Cancer Res. 2012 Jul 15;72(14):3642-51. doi: 10.1158/0008-5472.CAN-11-2008. Epub 2012 Apr 3.

3.

Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.

Begaye A, Trostel S, Zhao Z, Taylor RE, Schriemer DC, Sackett DL.

Cell Cycle. 2011 Oct 1;10(19):3387-96. doi: 10.4161/cc.10.19.17706. Epub 2011 Oct 1.

4.

Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells.

Komlodi-Pasztor E, Trostel S, Sackett D, Poruchynsky M, Fojo T.

Oncogene. 2009 Sep 3;28(35):3111-20. doi: 10.1038/onc.2009.166. Epub 2009 Jul 6.

5.

Oligomerization of p53 precedes its association with dynein and nuclear accumulation.

Trostel SY, Sackett DL, Fojo T.

Cell Cycle. 2006 Oct;5(19):2253-9. Epub 2006 Oct 1.

PMID:
16969106
6.

Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors.

Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S, Fojo T.

Cancer Res. 2005 Aug 15;65(16):7386-92.

Supplemental Content

Loading ...
Support Center